PPIB and Alzheimer disease: However, Lacanemab, another monoclonal antibody targeting Αβ deposits, was approved in July 2023 by the U.S. Food and Drug Administration.13, 14, 15 Lecanemab, also known as BAN2401, at 10 mg/kg biweekly, showed a significant effect on cognitive outcomes in AD.16